(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Exhibit No. | Description | ||||
99.1 | |||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
Eiger BioPharmaceuticals, Inc. | ||||||||
Dated: August 14, 2023 | ||||||||
By: | /s/ David Apelian | |||||||
David Apelian Chief Executive Officer |
June 30, 2023 | December 31, 2022(1) | ||||||||||
(Unaudited) | |||||||||||
ASSETS | |||||||||||
Cash and cash equivalents | $ | 22,983 | $ | 25,798 | |||||||
Short-term debt securities | 30,626 | 73,150 | |||||||||
Accounts receivable | 3,715 | 1,749 | |||||||||
Inventories | 1,098 | 2,853 | |||||||||
Prepaid expenses and other current assets | 12,062 | 13,985 | |||||||||
Total current assets | 70,484 | 117,535 | |||||||||
Property and equipment, net | 755 | 696 | |||||||||
Operating lease right-of-use assets | 329 | 561 | |||||||||
Other assets | 790 | 1,347 | |||||||||
Total assets | $ | 72,358 | $ | 120,139 | |||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
Current liabilities | 16,713 | $ | 25,121 | ||||||||
Other liabilities | 40,350 | 39,708 | |||||||||
Stockholders’ equity | 15,295 | 55,310 | |||||||||
Total liabilities and stockholders’ equity | $ | 72,358 | $ | 120,139 |
Three Months Ended June 30, (unaudited) | Six Months Ended June 30, (unaudited) | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Product revenue, net | $ | 4,393 | $ | 3,341 | $ | 8,511 | $ | 6,014 | |||||||||||||||
Other revenue | 250 | 750 | 250 | 750 | |||||||||||||||||||
Total revenue | 4,643 | 4,091 | 8,761 | 6,764 | |||||||||||||||||||
Costs and operating expenses: | |||||||||||||||||||||||
Cost of sales | (310) | 151 | (192) | 261 | |||||||||||||||||||
Research and development(1) | 19,401 | 16,993 | 36,149 | 34,563 | |||||||||||||||||||
Selling, general and administrative(1) | 5,533 | 7,027 | 15,048 | 13,840 | |||||||||||||||||||
Total operating expenses | 24,624 | 24,171 | 51,005 | 48,664 | |||||||||||||||||||
Loss from operations | (19,981) | (20,080) | (42,244) | (41,900) | |||||||||||||||||||
Interest expense | (1,343) | (934) | (2,628) | (1,820) | |||||||||||||||||||
Interest income | 660 | 221 | 1,371 | 266 | |||||||||||||||||||
Other income (expense), net | (29) | (1,074) | 26 | (1,047) | |||||||||||||||||||
Income (loss) before provision for taxes | (20,693) | (21,867) | (43,475) | (44,501) | |||||||||||||||||||
Provision for income taxes | 2 | 17 | 4 | 26 | |||||||||||||||||||
Net loss | $ | (20,695) | $ | (21,884) | $ | (43,479) | $ | (44,527) | |||||||||||||||
Net income (loss) per common share: | |||||||||||||||||||||||
Basic and diluted | $ | (0.47) | $ | (0.51) | $ | (0.98) | $ | (1.14) | |||||||||||||||
Weighted-average common shares outstanding: | |||||||||||||||||||||||
Basic and diluted | 44,296,417 | 43,059,809 | 44,221,442 | 39,178,043 |
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Research and development | $ | 517 | $ | 820 | $ | 1,351 | $ | — | $ | 1,445 | |||||||||||||
General and administrative | 228 | 1,388 | 1,936 | 2,810 | |||||||||||||||||||
Total stock-based compensation expense | $ | 745 | $ | 2,208 | $ | 3,287 | $ | 4,255 |
[7T'>!O'F3:<7.JEWB67RZ5<$B5WZ4[B].+TQ(GC6!)!RMVQ'??NN$LB
M *H72B0: 2R 78"=ZKT7JUM=5J]0[X4J% O*_-\[.R !@+F6]'O4-9<,GTOZ/:NL(EO2[V7Z?+EZ5;_!
MPH95;U!MZH9^8X65SH5MY^:"+=G>3^&VKU\U;-6^?E-A&X[TFQNW[4?Z+=E^
MANQ(OU7[8&?Z;6BU^G[;CZBV#W9&M2.P^L9^9X35PQI5:^06P]]?IK^_'(O%
M/B#NR W\'\)X=^4G2LM\7[ [.<
M?64PD?*0RMA]X\JC+J\2=>NX+E)MO-T37;-^ H\08D/&/X],9"KW:N, \H? WS(8:(%I#M-G3W;W2CU*K\.U$UCWO):
M)@5KTE@U$5PY.WK\I*"2GL62%6OY0!_JH5V_].:@NB]=N5;LK>^!B+GC 1H]
M8,IPGJ69/XB)_DH0P2!ZR0N&;TM2#@ &:M =ASI(!4_522\$5VYF$ QF4>WF
M^[]K^%%Z8),?2.Z_-2_BW7ZHDHZ B2-\"KA9/_1K0.&SJFH1OM:\H;_EQ^\H
MZ0R 1L=HN4QVK)7(\GA>Z(N: YIXZ3%(ET>*+S[56E\W8P^X*=K&SQ;N99NH?YE^UERHK]K&+E 5:]^B";M#;$
MIJX_PF9L/,;F;#[.YF\[P19M/\66[CS#5NPYRU;M.\?>/GB!;3ATB6T^7,^V
M';W,MA^_PG:=NL;VG6E@A\XULB,7&]FQ^F9V\G(+.WLUPBY
"3&FU6K2"VO(;6\E@U+4
=5B,Q#I^]IJY.$D^$3Z1\$:N3$"F#F-5\RW$W1N=]RW'T-#';
M[?)_TL.H.1+?TR;RYV:5:-YNMW_()BEK];J307J9G%YYI"B>,6B?7KU\ONJ+
MJ2!L,\VR\_HH=2G]K&7RJXXR__-.E_Q<-N8H4YZGE_W)4DEYS"HICZ=:B4=^
MPBKYGRF1I*Q\W_B-7J\C;GA&H$@[8]AW)B8:V*R3)/$>CB^H.1T_;G!G0(!D
M8J@+Z@TW&.YWNOW-\/'[9%[Q"C9R#>ES?%=7K AZ>>*OA28?JPB!+7/G:
M\(R;??Q%=^2I\;XF+Q%R9P?Y_%63SF/45.L[>MC0TC02T2;-^LL$^PZ&PM2-
MB=D]?MI7D)4OW!B=O#;$?
H%'[>6H3&Q>>5M)5D.2I(P&JZW3F)/&IX!4K9'266^5U0M(Y"XF(3KH[7/
MGC \:S:/_XQ++G\6BRJ(:G4#.#&3,@8Q/ZFJY7<]3?\_Y6+_^;*'O6GU1S#(
ME\U,OE0+5$\YYZVHN:SU'2(RILZ:&VMJ;LZ:VS!8N'C%ZJ9Q=G?$[O:SLN"D
MR*25>V(S-H1:\RTO$&IY&?Z-/"7BDOU]1%OL#H<'PB$P?>\>=L[W*?3
MW<2=&&6#Z)M6E/YW#U\46;0PP_8?A[M$_
MIW*9K1!_.PD'H^7W9"_0M7F3SND)0]Z;WV]WK;L#V1 S7 ,H%^_:+U^]KBD^
MX00^V:W;=_9*%$8BHH2IL^9EE;R(B#EZZ/"Q)-(]>^Y"=/:"Q3'L!XT/SG/&
MO$5-UQL;
B8;Z1CI"X]+Q*'#1_D,K$PB,A#:YU8J(V?.GT\;
M14(]A/"L^4N:D4=CO,W%5K^],::UH&I7T+W$;"ZGEKV)'I8?BRUMR#=]B @#
M+\T5P^]>4Y.NY->]F_Y?2]N/
Cover |
Aug. 14, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Aug. 14, 2023 |
Entity Registrant Name | EIGER BIOPHARMACEUTICALS, INC. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-36183 |
Entity Tax Identification Number | 33-0971591 |
Entity Address, Address Line One | 2155 Park Blvd. |
Entity Address, City or Town | Palo Alto |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94306 |
City Area Code | 650 |
Local Phone Number | 272-6138 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.001 |
Trading Symbol | EIGR |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Amendment Flag | false |
Entity Central Index Key | 0001305253 |
WAG4OE89U6"TZI6.Q&SQ^'WST;?RNZT*' LA&DNL!IVF!*9S+>.FZ"D%2X;V%]X8JY?X"?
MY,:[W&7,@N4CK ??F.U'P82[C\/%'(V&-XMG(E[@B9.#QP_:0_MS^).#_P)0
M2P$"% ,4 " P@0Y7;@E0%U(/ "+:P $0 @ $
M96EG